ZYBERNO
Stock Report
Updated Sep 1, 2026

IMMIX BIOPHARMA, INC. (IMMX)

Healthcare • NASDAQ

$13.94

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
18.0/100
POOR BUSINESS
IMMIX BIOPHARMA, INC. (IMMX) scores 18/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-38.4%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.01x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-232.2%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

IMMIX BIOPHARMA, INC. (IMMX) stock report — Zyberno Score 18/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, IMMX generated -$32.38M in Owner Earnings. Capital was deployed as follows: $697.70K invested in capital expenditures. Reinvestment rate: -1.6%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:13.94
Market Cap:$888.97M

Valuation Multiples (2)

P/B Ratio:3.88x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$673.56M

Price Action & Momentum (3)

Momentum Percentile:99 / 100
% of 52-Week High:92.3%
B. Profitability Assessment

Return Metrics (5)

ROA:-34.7%
Reinvestment Rate:-1.6%
Fundamental Growth Rate (g):3.6%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$6.31
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:25.13x
Quick Ratio:25.13x
Cash Ratio:24.24x

Leverage Analysis (3)

Debt To Equity Ttm:0.01x
Debt-to-Equity Ratio:0.01x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:224,488,366.00
Cash And Cash Equivalents:225,491,985.00
Long Term Debt:$890.64K
Net Debt:-$215.41M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$41.82M

Bottom Line Performance (3)

-$39.92M
Income Before Tax:-$39.88M
Ebitda Ttm:-41,484,313.00

Operating Expenses (5)

Operating Expenses:41,815,983.00
R And D Expense:21,624,715.00
Sga Expense:20,191,268.00
Income Tax Expense:$42.22K
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$239.11M
Current Assets:$233.79M
Ppe Net:2,358,428.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:10,192,343.00
Current Liabilities:9,301,705.00
Long Term Debt:$890.64K
Short Term Debt:$9.19M

Equity & Capital (3)

Equity:$228.92M
Retained Earnings:-$126.11M
Common Stock:200,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:5,280,229.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:575,565.00
C. Cash Flow Analysis

Operating Activities (2)

-$32.07M-$32.77M

Investment Activities (2)

Investing Cash Flow:-$4.80M
Capital Expenditures Ttm:697,698.00

Financing Activities (3)

Financing Cash Flow:-$37.56K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:107,392,716.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:331,670.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.88
-$0.88
Earnings Per Share Ttm:-$0.63

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$0.38

Book Value & Capital (2)

Book Value Per Share:$3.59
Cash Per Share:3.54

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$32.38M

Damodaran Growth Analysis (2)

Reinvestment Rate:-1.6%
Fundamental Growth Rate (g):3.6%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):40.7%
C. Company Profile & Context

Corporate Information (6)

Symbol:IMMX
Company Name:IMMIX BIOPHARMA, INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:63.77M
Shares Outstanding Basic:63.77M
Shares Outstanding Diluted:63.77M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 20:10:31 UTC
Data Timestamp:2026-09-01T20:10:31.543309
Scroll to Top